Study Reaffirms Favorable Outcomes for Small Papillary Thyroid Cancers
A small papillary thyroid cancer study demonstrates favorable outcomes and highlights the role of American Thyroid Association risk stratification.
Related Articles
Prostatectomy for Low-Grade Cancer Declines; Higher Risk Features More Common
Prostatectomy for grade group 1 prostate cancer significantly decreased from 2010 to 2024 in SEER and MUSIC data. Remaining cases show more high-risk features.
Frailty Predicts Docetaxel Tolerability in Metastatic Prostate Cancer
Frailty assessments, particularly the G8 tool, BMI, and albumin, may identify mHSPC patients at higher risk for severe adverse events with upfront docetaxel, a study…
Darolutamide/ADT Safe, Effective for Black Men with Metastatic Prostate Cancer
An ARANOTE substudy showed darolutamide plus ADT significantly improved outcomes (rPFS HR 0.51) and PSA suppression in Black men with mHSPC, with similar safety to…
Radical Prostatectomy Shows Less Genitourinary Toxicity in Localized Prostate Cancer
A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination…
First-Line Adagrasib Shows Activity in STK11-Mutant KRAS G12C NSCLC
Adagrasib shows initial promise, tolerability, and encouraging response rates in STK11/KRAS G12C-mutant lung cancer.
Cabozantinib/Nivolumab Efficacy, Safety Considered for Metastatic RCC
During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic renal cell carcinoma.
Kamran on the Shift Towards Early Salvage Radiation After Prostatectomy
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Novel CAR T Therapy Earns FDA Breakthrough Status for Incurable Pediatric Brain Tumor
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Enhanced NMIBC Progression Risk Prediction With a Novel AI Model
Jethro C.C. Kwong discusses a novel artificial intelligence-based model, PROGRxN-BCa.
First Patient Enrolled in ARID II Trial for Post-Prostatectomy Incontinence
Levee Medical has begun its pivotal ARID II trial, studying the Voro Scaffold for improved continence after prostatectomy.